CathWorks Appoints Chief Financial Officer
KFAR-SABA, ISRAEL & ALISO VIEJO, Calif.--(BUSINESS WIRE)--Mar 4, 2019--CathWorks announced that Mike Feher has joined CathWorks as Vice President of Finance and Chief Financial Officer. His appointment coincides with US commercialization of the CathWorks FFR angio™ System. Mr. Feher will initially focus on the development of financial and operational capabilities, as well as creating value for the organization through the execution of company’s strategy.
Mike joins CathWorks with over 13 years of finance and strategy experience in companies such as Edwards Lifesciences, Volcom and Deloitte. That experience includes deep understanding of investor relationships, strategic planning and financial operations. Mike is a certified public accountant. He earned his B.S. in Accounting, Finance and Economics from Chapman University and his MBA from University of Southern California.
Jim Corbett, CathWorks CEO, said of Mike’s appointment, “I am very excited to have Mike join our leadership team. Mike’s strategic mindset and broad financial acumen will be a significant addition to our team. The CathWorks System represents a tremendous opportunity for interventional cardiologists to improve the quality of care and lower costs in the treatment of multi-vessel coronary artery disease. I am confident in Mike’s ability to lead our finance organization as we continue to work towards achieving our strategic plan.”
Mr. Feher said, “I am excited about joining CathWorks and its dynamic leadership team. We look forward to the US commercialization of the CathWorks FFR angio in the next few weeks and cannot wait to see the impact of this transformational technology on patients, physicians, and health systems.”
The CathWorks FFR angio System quickly and precisely delivers the objective FFR guidance needed to optimize PCI therapy decisions for every patient. It is non-invasive and performed intra-procedurally during coronary angiography without adding additional clinical risk or per-procedure costs. The company received U.S. FDA 510(k) clearance for the CathWorks FFR angio Coronary Vascular Physiologic Simulation Software on December 19, 2018.
CathWorks is a medical technology company focused on applying its advanced computational science platform to optimize PCI therapy decisions and elevate coronary angiography from visual assessment to an objective FFR angio based decision-making tool for physicians. FFR-guided PCI decision-making is proven to provide significant clinical benefits for patients with coronary artery disease and economic benefits for patients and payers. The company’s focus is specifically on bringing the CathWorks FFR angio System to market to provide quick, precise, and objective intraprocedural FFR angio guidance that is practical for every case.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190304005199/en/
CONTACT: Media, Ramin Mousavi, +1.949.330.6903,firstname.lastname@example.org
Investors, Jim Corbett , +1.949.395.1214,email@example.com
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MIDDLE EAST ISRAEL
INDUSTRY KEYWORD: SURGERY TECHNOLOGY DATA MANAGEMENT VENTURE CAPITAL SOFTWARE HEALTH CARDIOLOGY MEDICAL DEVICES PROFESSIONAL SERVICES FINANCE
Copyright Business Wire 2019.
PUB: 03/04/2019 10:00 AM/DISC: 03/04/2019 10:01 AM